Fulcrum Therapeutics, Inc. - Special Call Transcript
Good morning, and thank you for joining Fulcrum Therapeutics Virtual KOL event featuring FTX-6058 for sickle cell disease. I'm Christi Waarich, Director of Investor Relations and Corporate Communications.
Just a few words before we get started. This is our disclaimer. Please refer to our most recent filings with the SEC for a discussion of certain risks and uncertainties associated with our business.
Before I turn it over to Robert Gould, Fulcrum's President and CEO, I'd like to remind you that today's presentation will be followed by a Q&A session. (Operator Instructions)
Thank you again for joining us. I'd now like to turn it over to Robert. Robert?
Thank you, Christi, and thank you, everybody, for joining us on this webinar on our sickle cell disease program. We're very excited to present this program to you today for 2 reasons. First of all, for the potential
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |